Followers | 3819 |
Posts | 240126 |
Boards Moderated | 0 |
Alias Born | 07/30/2007 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, July 24, 2021 3:30:05 PM
NRX Pharmaceuticals Inc (NASDAQ: NRXP) Announces the Beginning of Crisis use Exercise and Addition of Phase 2/3 Inhaled ZYESAMI™ Pilot in Georgia
Posted By Jacob Peter on July 24, 2021
NRX Pharmaceuticals Inc (NASDAQ: NRXP) announced it is starting scientific training of Nation of Georgia (Georgia) ICU doctors in the use of circulatory ZYESAMI™ for crisis use in patients suffering from Acute COVID-19, and gasped ZYESAMI™ for usage in phase 2/3 scientific trials, for patients in sorrow with COVID-19.
NRx lengthens its unending Phase 2/3 pilot of gasped ZYESAMI™ to Georgia
NRx also announced that the continuing stage 2/3 pilot for the usage of gasped ZYESAMI™ has stretched to Georgia, with the latent to also spread to bordering nations in the Caucasus region, in collaboration with Cromos, LLC and Denk Pharma (Georgia), working as BriLife, LLC. NRx imagines shipping medical drug provisions to Georgia within two weeks. The growth of intravenous Aviptadil-acetate, in non-GMP form, was partially funded by a partnership contract with RELIEF THERAPEUTICS Holding SA (OTCMKTS: RLFTF).
NRx Pharmaceuticals poses suggestion that ZYESAMI™ (aviptadil) aids avert “Cytokine Squall” in Patients with COVID-19
In other news, the company announced that it would be presenting statistics at the Disease Control and Prevention Summit on July 21, 2021. The demonstration recognizes a statistically significant consequence of ZYESAMI™ (aviptadil) in stopping the relentless increase in cytokines, usually related to death in patients with COVID-19.
In the recently completed stage 2b/3 pilot, patients cured with placebo underwent a statistically noteworthy advancement in interleukin 6 (IL-6) cytokine echelons, while those cured with ZYESAMI™ had a negligible surge in IL-6.
Health watchdogs endure highlighting treatments for COVID-19 which help hinder the influence of IL-6 cytokines in patients with COVID-19. The anti-cytokine consequence of ZYESAMI™ was furthermore related to a noteworthy reduction in 60-day death.
The consequence was prominent across various patients, suffering different stages of COVID-19 relentlessness and cured in both tertiary care and public infirmaries.
Posted in Business Tagged NASDAQ NRXP, NRX Pharmaceuticals Inc (NASDAQ: NRXP), NRXP, NRXP News, NRXP Stock
https://topnewsguide.com/2021/07/24/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-the-beginning-of-crisis-use-exercise-and-addition-of-phase-2-3-inhaled-zyesami-pilot-in-georgia/
Recent NRXP News
- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 • PR Newswire (US) • 06/20/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors • PR Newswire (US) • 06/18/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter • PR Newswire (US) • 06/10/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipola • PR Newswire (US) • 05/28/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 05/14/2024 08:01:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 • PR Newswire (US) • 05/08/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 • PR Newswire (US) • 05/07/2024 08:01:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression • PR Newswire (US) • 05/06/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression • PR Newswire (US) • 04/30/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement • PR Newswire (US) • 04/18/2024 12:32:00 PM
- NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/18/2024 12:30:00 PM
- NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock • PR Newswire (US) • 04/17/2024 08:45:00 PM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections • PR Newswire (US) • 04/17/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) • PR Newswire (US) • 04/15/2024 12:30:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression • PR Newswire (US) • 04/08/2024 12:30:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 04/01/2024 12:28:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights • PR Newswire (US) • 03/28/2024 12:03:00 PM
- NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 03/28/2024 12:00:00 PM
- NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • PR Newswire (US) • 03/26/2024 08:03:00 PM
- NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK • PR Newswire (US) • 03/25/2024 12:30:00 PM
- NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024 • PR Newswire (US) • 03/21/2024 08:02:00 PM
- NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders • PR Newswire (US) • 03/21/2024 05:57:00 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales • PR Newswire (US) • 03/12/2024 11:49:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/11/2024 09:16:06 PM
- NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) • PR Newswire (US) • 03/11/2024 12:30:00 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM